Luke Greenwalt of IQVIA on Obesity Drug Market | Asembia 2024
In an interview before the Asembia meeting, Luke Greenwalt, MBA, vice president, market access for IQVIA, discussed the hot topic of the meeting — GLP-1s and the obesity market.
"Over the next five years we are going to see this space get super intense. We are going to see a lot of products comes in," Greenwalt said.
IQVIA is tracking 100 new possible drugs for obesity in development and that the global market could reach $100 billion, he said.
The obesity drugs could lead to more diagnoses of obesity-related health conditions and therefore more prescriptions to treat those conditions, Geenwalt added.
Over the long run, though, he noted the the GLP-1s and other obesity-related drugs could lessen demand for those treatments if people lose weight and therefore experience fewer diseases caused by obesity and being overweight.
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
